Ipsen Pharma SAS, a leading global biopharmaceutical group headquartered in France, is renowned for its innovative approach in the healthcare industry. Founded in 1929, Ipsen has established a strong presence in key operational regions, including Europe, North America, and Asia. The company focuses on developing and commercialising specialty medicines in areas such as oncology, neuroscience, and rare diseases. Ipsen's core products, including Somatuline® and Dysport®, are distinguished by their unique formulations and targeted therapeutic applications, addressing critical patient needs. With a commitment to research and development, Ipsen has achieved notable milestones, positioning itself as a trusted partner in the biopharmaceutical landscape. The company’s dedication to improving patient outcomes has solidified its reputation as a leader in the industry.
We don't have data for Ipsen Pharma SAS, but we can show you information about their parent organization instead.
View parent company